1. Home
  2. IGC vs TRIB Comparison

IGC vs TRIB Comparison

Compare IGC & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGC
  • TRIB
  • Stock Information
  • Founded
  • IGC 2005
  • TRIB 1992
  • Country
  • IGC United States
  • TRIB Ireland
  • Employees
  • IGC N/A
  • TRIB N/A
  • Industry
  • IGC Biotechnology: Pharmaceutical Preparations
  • TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • IGC Health Care
  • TRIB Health Care
  • Exchange
  • IGC Nasdaq
  • TRIB Nasdaq
  • Market Cap
  • IGC 29.4M
  • TRIB 24.0M
  • IPO Year
  • IGC N/A
  • TRIB N/A
  • Fundamental
  • Price
  • IGC $0.33
  • TRIB $1.32
  • Analyst Decision
  • IGC Strong Buy
  • TRIB
  • Analyst Count
  • IGC 2
  • TRIB 0
  • Target Price
  • IGC $3.75
  • TRIB N/A
  • AVG Volume (30 Days)
  • IGC 380.9K
  • TRIB 6.1M
  • Earning Date
  • IGC 02-12-2025
  • TRIB 11-15-2024
  • Dividend Yield
  • IGC N/A
  • TRIB N/A
  • EPS Growth
  • IGC N/A
  • TRIB N/A
  • EPS
  • IGC N/A
  • TRIB N/A
  • Revenue
  • IGC $1,183,000.00
  • TRIB $59,126,000.00
  • Revenue This Year
  • IGC N/A
  • TRIB $11.63
  • Revenue Next Year
  • IGC $13.38
  • TRIB $10.13
  • P/E Ratio
  • IGC N/A
  • TRIB N/A
  • Revenue Growth
  • IGC N/A
  • TRIB N/A
  • 52 Week Low
  • IGC $0.27
  • TRIB $0.74
  • 52 Week High
  • IGC $0.91
  • TRIB $3.55
  • Technical
  • Relative Strength Index (RSI)
  • IGC 41.18
  • TRIB 70.29
  • Support Level
  • IGC $0.31
  • TRIB $0.74
  • Resistance Level
  • IGC $0.37
  • TRIB $1.04
  • Average True Range (ATR)
  • IGC 0.02
  • TRIB 0.11
  • MACD
  • IGC -0.00
  • TRIB 0.06
  • Stochastic Oscillator
  • IGC 28.17
  • TRIB 78.38

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

About TRIB Trinity Biotech plc

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Share on Social Networks: